# US 2012/0251494 A1 · Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251494 A1
- Document ID: US20120251494A1
- Status: Published application
- Kind: A1
- Application number: 13/397,834
- Filed: 2012-02-16
- Published: 2012-10-04
- Earliest claimed: 2006-05-03
- Assignees: The Regents of the University of Colorado
- Inventors: Ross Kedl; Phillip J. Sanchez; Catherine Haluszczak
- Web page: https://patentgrep.com/patent/US20120251494A1

## CPC

- C07K 14/555: Interferons [IFN]
- A61K 39/12: Viral antigens
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/285: Vaccinia virus or variola virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/642: {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.

## Claims

### Claim at position 1

1-79. (canceled)

### Claim 80

An immunostimulatory regimen for inducing CD70 expression on dendritic cells and inducing the expansion of CD8+ T cells in a subject in need thereof and thereby eliciting an anti-infectious immune response comprising administering type 1 interferon and an immune agonist polypeptide other than said type 1 interferon, and further including the administration of an infectious agent antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide other than said type 1 interferon administered in said immunostimulatory regimen consists of an agonistic CD40L polypeptide or a CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide, and further wherein said agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type 1 interferons are administered in amounts that in combination, but not separately, result in the induction of CD70 expression on dendritic cells.

### Claim 81

An immunostimulatory regimen for inducing the expansion of CD8+ T cells in a subject in need thereof and eliciting an anti-infectious agent immune response by administering a type 1 interferon and an immune agonist polypeptide other than said type 1 interferon and further including the administration of an infectious antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide administered -in said immunostimulatory regimen other than said type 1 interferon consists of a an agonistic CD40L polypeptide or CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide and wherein said an agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type 1 interferon are administered in amounts that in combination, but not separately, result in the expansion of CD8+ T cells.

### Claim 82

An immunostimulatory therapeutic regimen for inducing primary and memory T cell responses in a subject in need thereof and eliciting an anti-infectious agent immune response by administering type 1 interferon and an immune agonist polypeptide other than said type 1 interferon and another further including an infectious agent antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide used in said immunostimulatory regimen other than said type 1 interferon consists of a an agonistic CD40L polypeptide or CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide and wherein said an agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type interferon are administered in amounts that in combination, but not separately, result in a synergistic effect on immunity resulting in enhanced primary and memory CD8+ T cell responses specific to the infectious agent.

### Claim 83 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon are administered as discrete entities.

### Claim 84 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon are administered as discrete entities.

### Claim 85 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious agent antigen are administered as discrete entities.

### Claim 86 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious agent antigen are administered as discrete entities in combination.

### Claim 87 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious agent antigen are administered as discrete entities in combination.

### Claim 88 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon are administered as discrete entities in combination.

### Claim 89 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious antigen are separately administered as discrete entities.

### Claim 90 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious antigen are separately administered as discrete entities.

### Claim 91 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment, type 1 interferon and infectious antigen are separately administered as discrete polypeptides entities in combination.

### Claim 92 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the type 1 interferon is an alpha or beta interferon.

### Claim 93 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the type 1 interferon is an alpha or beta interferon.

### Claim 94 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the type 1 interferon is an alpha or beta interferon.

### Claim 95 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the type 1 interferon is a human alpha or beta interferon.

### Claim 96 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the type 1 interferon is a human alpha or beta interferon.

### Claim 97 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the type 1 interferon is a human alpha or beta interferon.

### Claim 98 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the type 1 interferon is PEGylated.

### Claim 99 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the type 1 interferon is PEGylated.

### Claim 100 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the type 1 interferon is PEGylated.

### Claim 101 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the CD40 agonistic antibody or fragment is an agonistic chimeric, human, or humanized anti-CD40 antibody or an agonistic CD40 antibody fragment which is selected from a Fab, F(ab′)2, Fd, and a Fv.

### Claim 102 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the CD40 agonist is an agonistic chimeric, human, or humanized anti-CD40 antibody or an agonistic CD40 antibody fragment which is selected from a Fab, F(ab′)2, Fd, and a Fv.

### Claim 103 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the CD40 agonist is an agonistic chimeric, human, or humanized anti-CD40 antibody or an agonistic CD40 antibody fragment which is selected from a Fab, F(ab′)2, Fd, and a Fv.

### Claim 104 (depends on 80)

The immunostimulatory regimen of claim 80 wherein said type 1 interferon is selected from alpha interferon, beta interferon, omega interferon, tau interferon, zeta interferon and epsilon interferon.

### Claim 105 (depends on 81)

The immunostimulatory regimen of claim 81 wherein said type 1 interferon is selected from alpha interferon, beta interferon, omega interferon, tau interferon, zeta interferon and epsilon interferon.

### Claim 106 (depends on 82)

The immunostimulatory regimen of claim 82 wherein said type 1 interferon is selected from alpha interferon, beta interferon, omega interferon, tau interferon, zeta interferon and epsilon interferon.

### Claim 107 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 24 hours of each other.

### Claim 108 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 24 hours of each other.

### Claim 109 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 24 hours of each other.

### Claim 110 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 1-8 hours of each other.

### Claim 111 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 1-8 hours of each other.

### Claim 112 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or agonistic CD40 antibody or antibody fragment and the type 1 interferon are administered within 1-8 hours of each other.

### Claim 113 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment and the type 1 interferon are administered at the same time.

### Claim 114 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or fragment and the type I interferon are administered at the same time.

### Claim 115 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the an agonistic CD40L polypeptide or CD40 agonistic antibody or antibody fragment and the type 1 interferon are administered at the same time.

### Claim 116 (depends on 80)

The regimen of claim 80 wherein the infectious agent is a bacterium, virus, fungus, mycoplasm, or parasite.

### Claim 117 (depends on 81)

The regimen of claim 81 wherein the infectious agent is a bacterium, virus, fungus, mycoplasm, or parasite.

### Claim 118 (depends on 82)

The regimen of claim 82 wherein infectious agent is a bacterium, virus, fungus, mycoplasm, or parasite.

### Claim 119 (depends on 80)

The regimen of claim 80 wherein the infectious agent is a gram positive or gram negative bacterium.

### Claim 120 (depends on 81)

The regimen of claim 81 wherein the infectious agent is a gram positive or gram negative bacterium.

### Claim 121 (depends on 82)

The regimen of claim 82 wherein the infectious agent is a gram positive or gram negative bacterium.

### Claim 122 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the infectious agent is a gram positive or gram negative bacterium selected from a Pasteurella species, Staphylococci species, Streptococci species, Escherichia coli, Pseudomonas species, Salmonella species, Heliobacter pyloris, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. selected from M. tuberculosis, M. avium, M. intracellilare, M. kansaii, and M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogeners, Streptococcus pyogenes, (group A Streptococcus), Streptococcus agalactiae(Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (aenorobic spp.), Streptococcus pneumoniae, pathogenic Campylobacter spp., Enterococcus spp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diptheriae, Corynebacterium spp., Erysipelothrix rhusiopathie, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides spp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelii.

### Claim 123 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the infectious agent is a gram positive or gram negative bacterium selected from a Pasteurella species, Staphylococci species, Streptococci species, Escherichia coli, Pseudomonas species, Salmonella species, Heliobacter pyloris, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. selected from M. tuberculosis, M. avium, M. intracellilare, M. kansaii, and M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogeners, Streptococcus pyogenes, (group A Streptococcus), Streptococcus agalactiae(Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (aenorobic spp.), Streptococcus pneumoniae, pathogenic Campylobacter spp., Enterococcus spp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diptheriae, Corynebacterium spp., Erysipelothrix rhusiopathie, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides spp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelii.

### Claim 124 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the infectious agent is a gram positive or gram negative bacterium selected from a Pasteurella species, Staphylococci species, Streptococci species, Escherichia coli, Pseudomonas species, Salmonella species, Heliobacter pyloris, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. selected from M. tuberculosis, M. avium, M. intracellilare, M. kansaii, and M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogeners, Streptococcus pyogenes, (group A Streptococcus), Streptococcus agalactiae(Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (aenorobic spp.), Streptococcus pneumoniae, pathogenic Campylobacter spp., Enterococcus spp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diptheriae, Corynebacterium spp., Erysipelothrix rhusiopathie, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides spp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelii.

### Claim 125 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the infectious agent is a fungus or mycoplasm.

### Claim 126 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the infectious agent is a fungus or mycoplasm.

### Claim 127 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the infectious agent is a fungus or mycoplasm.

### Claim 128 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the infectious agent is a fungus selected from Coccidoides immitis, Cryptococcus neoformans, Candida albicans Blastomyces dermatidis, Histoplasma capsulatum, Chlamydia trachomatis, Nocardia spp., and Pneumocytis carinii.

### Claim 129 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the infectious agent is a fungus fungus selected from Coccidoides immitis, Cryptococcus neoformans, Candida albicans Blastomyces dermatidis, Histoplasma capsulatum, Chlamydia trachomatis, Nocardia spp., and Pneumocytis carinii.

### Claim 130 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the infectious agent is a fungus fungus selected from Coccidoides immitis, Cryptococcus neoformans, Candida albicans Blastomyces dermatidis, Histoplasma capsulatum, Chlamydia trachomatis, Nocardia spp., and Pneumocytis carinii.

### Claim 131 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 132 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 133 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 134 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 135 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 136 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 137 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 138 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 139 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are comprised in the same or different compositions.

### Claim 140 (depends on 80)

The immunostimulatory regimen of claim 80 which is effected in a patient with an infectious disorder.

### Claim 141 (depends on 81)

The immunostimulatory regimen of claim 81 which is effected in a patient with an infectious disorder.

### Claim 142 (depends on 82)

The immunostimulatory regimen of claim 82 which is effected in a patient with an infectious disorder.

### Claim 143 (depends on 80)

The immunostimulatory regimen of claim 80 wherein the CD40L, CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are administered mucosally, topically, orally, intravenously, intramuscularly, intranasally, vaginally, rectally, intratumorally, intrathecally, or intraocularly.

### Claim 144 (depends on 81)

The immunostimulatory regimen of claim 81 wherein the CD40L, CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are administered mucosally, topically, orally, intravenously, intramuscularly, intranasally, vaginally, rectally, intratumorally, intrathecally, or intraocularly.

### Claim 145 (depends on 82)

The immunostimulatory regimen of claim 82 wherein the CD40L, CD40 agonistic antibody or antibody fragment, the type 1 interferon and the infectious antigen are administered mucosally, topically, orally, intravenously, intramuscularly, intranasally, vaginally, rectally, intratumorally, intrathecally, or intraocularly.
